Gore has announced Food and Drug Administration (FDA) approval for the Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE), which the company states is the first off-the-shelf endovascular solution for the treatment of complex aneurysmal disease involving the visceral aorta.
A press release details that U.S. physicians have had limited options for treating patients with aortic aneurysms involving the visceral branch vessels, with the current standard of open surgical repair being complex and associated with a high rate of mortality and morbidity. It continues that existing options for a minimally invasive approach are limited to products not designed for this purpose or custom-built devices—when and if the patient’s anatomy qualifies them—which can delay treatment due to manufacturing time.
“Until now, endovascular treatment options were limited as alternatives to open surgical repair,” said Mark A. Farber, MD, national principal investigator. “TAMBE is an innovative first step forward that enables us to provide care that’s both effective and timely for complex aneurysm repair.”
TAMBE is an implantable branched device designed for use in patients with thoracoabdominal aortic aneurysms (TAAA) and high-surgical risk patients with pararenal aortic aneurysms (PAAA) of the aorta using an endovascular approach in which the physician guides the device through arteries in the groin and arm via small incisions. Using established imaging techniques, the physician deploys the device to seal off the aneurysm, allowing blood to flow directly through the endoprosthesis.
TAMBE has four built-in, pre-cannulated internal portals to facilitate placement of bridging stent grafts into the visceral arteries perfusing the internal organs within the abdomen. It is expected to become available in June 2024.
